Duchenne Muscular Dystrophy Treatment Market Research Report Information By Therapeutic Approaches (Molecular-based Therapies (Mutation Suppression, Exon Skipping), Steroid Therapy (Corticosteroids), and Other Therapeutic Approaches) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES

6.1. Overview

6.2. Molecular-base Therapies

6.2.1. Mutation Suppression

6.2.2. Exon Skipping

6.3. Steroid Therapy

6.3.1. Corticosteroids

6.4. Other Therapeutic Approaches

7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION

7.1. Overview

7.1. North America

7.1.1. US

7.1.2. Canada

7.2. Europe

7.2.1. Germany

7.2.2. France

7.2.3. UK

7.2.4. Italy

7.2.5. Spain

7.2.6. Rest of Europe

7.3. Asia-Pacific

7.3.1. China

7.3.2. India

7.3.3. Japan

7.3.4. South Korea

7.3.5. Australia

7.3.6. Rest of Asia-Pacific

7.4. Rest of the World

7.4.1. Middle East

7.4.2. Africa

7.4.3. Latin America

8. COMPETITIVE LANDSCAPE

8.1. Overview

8.2. Competitive Analysis

8.3. Market Share Analysis

8.4. Major Growth Strategy in the Global Duchenne Muscular Dystrophy Treatment Market,

8.5. Competitive Benchmarking

8.6. Leading Players in Terms of Number of Developments in the Global Duchenne Muscular Dystrophy Treatment Market,

8.7. Key Developments and Growth Strategies

8.7.1. New Product Launch/Service Deployment

8.7.2. Merger & Acquisitions

8.7.3. Joint Ventures

8.8. Major Players Financial Matrix

8.8.1. Sales & Operating Income, 2023

8.8.2. Major Players R&D Expenditure. 2023

9. COMPANY PROFILES

9.1. BioMarin

9.1.1. Company Overview

9.1.2. Financial Overview

9.1.3. Products Offered

9.1.4. Key Developments

9.1.5. SWOT Analysis

9.1.6. Key Strategies

9.2. Fibrogen.

9.2.1. Company Overview

9.2.2. Financial Overview

9.2.3. Products Offered

9.2.4. Key Developments

9.2.5. SWOT Analysis

9.2.6. Key Strategies

9.3. Nobelpharma Co. Ltd

9.3.1. Company Overview

9.3.2. Financial Overview

9.3.3. Products Offered

9.3.4. Key Developments

9.3.5. SWOT Analysis

9.3.6. Key Strategies

9.4. NS Pharma Inc

9.4.1. Company Overview

9.4.2. Financial Overview

9.4.3. Products Offered

9.4.4. Key Developments

9.4.5. SWOT Analysis

9.4.6. Key Strategies

9.5. Pfizer Inc

9.5.1. Company Overview

9.5.2. Financial Overview

9.5.3. Products Offered

9.5.4. Key Developments

9.5.5. SWOT Analysis

9.5.6. Key Strategies

9.6. PTC Therapeutics

9.6.1. Company Overview

9.6.2. Financial Overview

9.6.3. Products Offered

9.6.4. Key Developments

9.6.5. SWOT Analysis

9.6.6. Key Strategies

9.7. Santhera Pharmaceuticals

9.7.1. Company Overview

9.7.2. Financial Overview

9.7.3. Products Offered

9.7.4. Key Developments

9.7.5. SWOT Analysis

9.7.6. Key Strategies

9.8. Sarepta Therapeutics

9.8.1. Company Overview

9.8.2. Financial Overview

9.8.3. Products Offered

9.8.4. Key Developments

9.8.5. SWOT Analysis

9.8.6. Key Strategies

9.9. F. Hoffmann-La Roche AG

9.9.1. Company Overview

9.9.2. Financial Overview

9.9.3. Products Offered

9.9.4. Key Developments

9.9.5. SWOT Analysis

9.9.6. Key Strategies

9.10. ReveraGen BioPharma

9.10.1. Company Overview

9.10.2. Financial Overview

9.10.3. Products Offered

9.10.4. Key Developments

9.10.5. SWOT Analysis

9.10.6. Key Strategies

10. APPENDIX

10.1. References

10.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 4 NORTH AMERICA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 5 US: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 6 CANADA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 2 GERMANY: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 3 FRANCE: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 4 ITALY: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 5 SPAIN: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 6 UK: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 7 REST OF EUROPE: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 8 ASIA-PACIFIC: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 9 JAPAN: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 10 CHINA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 11 INDIA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 12 AUSTRALIA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 13 SOUTH KOREA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 14 REST OF ASIA-PACIFIC: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 15 REST OF THE WORLD: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 16 MIDDLE EAST: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 17 AFRICA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

TABLE 18 LATIN AMERICA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPEUTIC APPROACHES, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET

FIGURE 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY THERAPEUTIC APPROACHES, 2023

FIGURE 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY REGION, 2023

FIGURE 6 NORTH AMERICA: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 EUROPE: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 ASIA-PACIFIC: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 REST OF THE WORLD: DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 11 BIOMARIN: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 12 BIOMARIN: SWOT ANALYSIS

FIGURE 13 FIBROGEN INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 FIBROGEN INC: SWOT ANALYSIS

FIGURE 15 NOBELPHARMA CO LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 NOBELPHARMA CO LTD: SWOT ANALYSIS

FIGURE 17 NS PHARMA INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 NS PHARMA INC: SWOT ANALYSIS

FIGURE 19 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 PFIZER INC.: SWOT ANALYSIS

FIGURE 21 PTC THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 PTC THERAPEUTICS: SWOT ANALYSIS

FIGURE 23 SANTHERA PHARMACETICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 SANTHERA PHARMACETICALS: SWOT ANALYSIS

FIGURE 25 SAREPTA THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 SAREPTA THERAPEUTICS: SWOT ANALYSIS

FIGURE 27 F.HOFFMANN-LA ROCHE AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 F.HOFFMANN-LA ROCHE AG: SWOT ANALYSIS

FIGURE 29 REVERAGEN BIOPHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 REVERAGEN BIOPHARMA: SWOT ANALYSIS